The Enterolimbic Axis: How Gut Peptides Like GLP-1 Control Appetite, Mood, and Reward

The enterolimbic axis framework integrates gut peptide signaling (GLP-1, GIP) with reward processing and emotional regulation, positioning gastroenterologists as key prescribers of incretin therapies for metabolic and eating disorders.

Gasbarrini, Antonio et al.·The American journal of gastroenterology·2026·
RPEP-151982026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

The enterolimbic axis integrates gut-derived GLP-1, GIP, and SCFAs with hypothalamic and mesolimbic reward pathways, supporting the repositioning of incretin therapies for metabolic, eating, and affective disorders.

Key Numbers

How They Did This

Conceptual review integrating molecular, clinical, and therapeutic evidence on the enterolimbic axis and its implications for precision medicine.

Why This Research Matters

Understanding that gut peptides control both metabolism and mood/reward redefines how we think about obesity, eating disorders, and mental health — and who should prescribe treatments.

The Bigger Picture

The enterolimbic axis bridges gastroenterology, endocrinology, and psychiatry, revealing that gut peptides are central regulators of both physical and mental health.

What This Study Doesn't Tell Us

Conceptual framework. Direct evidence for some proposed pathways is limited. Clinical applications are emerging but not fully validated.

Questions This Raises

  • ?Should GLP-1 drugs be prescribed by gastroenterologists for eating disorders?
  • ?How do gut microbiota changes affect enterolimbic signaling?
  • ?Can the enterolimbic framework improve precision medicine for obesity?

Trust & Context

Key Stat:
Gut → mood → metabolism The enterolimbic axis shows gut peptides simultaneously regulate metabolism, emotional states, and reward processing
Evidence Grade:
Conceptual review with supporting molecular and clinical evidence. Novel framework needing prospective validation.
Study Age:
Published in 2025.
Original Title:
The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior.
Published In:
The American journal of gastroenterology (2026)
Database ID:
RPEP-15198

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is the enterolimbic axis?

It's a framework describing how gut hormones like GLP-1 connect to brain emotion and reward centers. This explains why GLP-1 drugs affect not just weight and blood sugar, but also mood, food cravings, and potentially addiction.

Could my gut health affect my mental health?

Yes. The enterolimbic axis shows that gut bacteria produce molecules that influence brain reward and emotional circuits through peptide hormones like GLP-1 and GIP, connecting digestive health directly to mental well-being.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-15198·https://rethinkpeptides.com/research/RPEP-15198

APA

Gasbarrini, Antonio; Galli, Francesca Sofia; Ianiro, Gianluca; Ponziani, Francesca; Rinninella, Emanuele. (2026). The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior.. The American journal of gastroenterology. https://doi.org/10.14309/ajg.0000000000003907

MLA

Gasbarrini, Antonio, et al. "The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior.." The American journal of gastroenterology, 2026. https://doi.org/10.14309/ajg.0000000000003907

RethinkPeptides

RethinkPeptides Research Database. "The Enterolimbic Axis: Gut-Brain Affective Circuits at the C..." RPEP-15198. Retrieved from https://rethinkpeptides.com/research/gasbarrini-2026-the-enterolimbic-axis-gutbrain

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.